Japan Looks To Build Domestic Capacity In New Modalities

New Govt Funding For CGT Production

Japan's trade ministry is providing new support to build domestic capacity for new modalities including cell and gene therapies, as part of wider efforts to support the national bioventure ecosystem.

Japan's cell and gene therapy support
Japan's METI has budgeted JPY38.3bn to support building domestic CDMOs for cell and gene therapy. (Shutterstock)

Japan’s attempts to strengthen its bioventure ecosystem have received another boost through broadened financial support for the domestic production of cell and gene therapies from the Ministry of Economy, Trade and Industry (METI).

One of the country’s key national projects for the biopharmaceutical sector is the multi-year Drug Discovery Venture Ecosystem initiative, which aims to invest a total of up to JPY350bn ($2

METI has now budgeted a further JPY5.8bn to assist the R&D of biopharma manufacturing technologies in Japan, which is separate from another JPY38

More from Japan

More from Advanced Technologies